Q3 Earnings Forecast for AnaptysBio Issued By HC Wainwright

AnaptysBio, Inc. (NASDAQ:ANAB) – Stock analysts at HC Wainwright boosted their Q3 2026 earnings estimates for AnaptysBio in a research note issued to investors on Tuesday, September 22nd. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will earn $0.00 per share for the quarter, up from their prior estimate of ($0.03). HC Wainwright currently has a “Buy” rating and a $95.00 target price on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($2.06) per share. HC Wainwright also issued estimates for AnaptysBio’s FY2026 earnings at ($1.30) EPS, FY2027 earnings at $2.42 EPS, FY2028 earnings at $4.57 EPS, FY2029 earnings at $5.23 EPS and FY2030 earnings at $6.50 EPS.

Several other research firms have also recently weighed in on ANAB. TD Cowen decreased their price target on shares of AnaptysBio from $75.00 to $70.00 and set a “buy” rating on the stock in a report on Tuesday, August 25th. Weiss Ratings reissued a “sell (e+)” rating on shares of AnaptysBio in a research note on Friday, August 7th. Zacks Research cut AnaptysBio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. Scotiabank lowered AnaptysBio to a “hold” rating and set a $70.00 target price on the stock. in a research note on Tuesday, August 25th. Finally, Leerink Partners lowered their price target on AnaptysBio from $90.00 to $81.00 and set an “outperform” rating on the stock in a report on Wednesday. Twelve equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $79.15.

AnaptysBio Price Performance

Shares of NASDAQ:ANAB opened at $50.77 on Thursday. The firm has a fifty day moving average price of $55.57 and a two-hundred day moving average price of $59.17. AnaptysBio has a one year low of $13.86 and a one year high of $72.36. The company has a market cap of $1.50 billion, a price-to-earnings ratio of 9.45 and a beta of 0.71.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Monday, September 21st. The biotechnology company reported $5.11 EPS for the quarter, beating the consensus estimate of ($0.46) by $5.57. The company had revenue of $27.49 million during the quarter, compared to analysts’ expectations of $14.06 million. AnaptysBio had a net margin of 82.37% and a return on equity of 112.00%. During the same quarter in the previous year, the company earned ($1.30) earnings per share.

Institutional Investors Weigh In On AnaptysBio

Several hedge funds have recently added to or reduced their stakes in ANAB. First Light Asset Management LLC boosted its holdings in shares of AnaptysBio by 2.9% in the 2nd quarter. First Light Asset Management LLC now owns 582,004 shares of the biotechnology company’s stock worth $39,285,000 after purchasing an additional 16,573 shares in the last quarter. Squarepoint Ops LLC lifted its position in AnaptysBio by 21.2% in the 2nd quarter. Squarepoint Ops LLC now owns 324,446 shares of the biotechnology company’s stock worth $21,900,000 after buying an additional 56,743 shares during the last quarter. Arizona State Retirement System boosted its stake in AnaptysBio by 13.5% in the second quarter. Arizona State Retirement System now owns 4,363 shares of the biotechnology company’s stock worth $295,000 after buying an additional 518 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in AnaptysBio in the second quarter worth approximately $1,164,000. Finally, Irenic Capital Management LP bought a new position in AnaptysBio during the second quarter valued at approximately $4,755,000.

More AnaptysBio News

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $95 price target, while raising its Q3 2026 EPS forecast to $0.00 from a projected loss of $0.03 and improving its FY2026 estimate to a loss of $1.30 per share from a loss of $2.60. The firm still expects AnaptysBio to become profitable beginning in FY2027.
• Positive Sentiment: AnaptysBio’s latest quarterly results substantially exceeded expectations, with $5.11 in EPS versus the consensus estimate of a $0.46 loss and revenue of $27.49 million versus expectations of $14.06 million. However, the profit was helped by a substantial $181.5 million tax benefit, which may limit the recurring significance of the earnings beat. AnaptysBio Swings To Profit in Q2 Reflecting $181.5 Million Tax Benefit
• Positive Sentiment: Leerink Partners continues to rate the stock Outperform and its revised $81 price target implies significant upside from the referenced $50.77 level, although the target was reduced from $90. AnaptysBio analyst information
• Neutral Sentiment: Analyst coverage remains broadly constructive: AnaptysBio has received an average “Moderate Buy” recommendation, with analysts focusing on the company’s potential transition to sustained profitability.
• Negative Sentiment: HC Wainwright cut its longer-term EPS forecasts for FY2027 through FY2030: FY2027 to $2.42 from $2.86, FY2028 to $4.57 from $5.42, FY2029 to $5.23 from $6.20, and FY2030 to $6.50 from $7.64. These reductions suggest a more cautious view of AnaptysBio’s eventual earnings power despite the unchanged Buy rating and $95 target.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines for cancer and immune-mediated diseases. The company’s programs are designed to modulate immune-cell signaling and address conditions in which the immune system is either insufficiently active, as in cancer, or overly active, as in autoimmune and inflammatory disorders.

AnaptysBio’s pipeline has included rosnilimab, an investigational antibody targeting CD200R1, and other immune-cell modulators aimed at autoimmune and inflammatory diseases.